MassDevice Q&A: Susan Windham-Bannister, Part I

March 30, 2009 by Brian Johnson

The head of the Bay State's Life Sciences Center explains the difference between $1 billion and $33 million.

Susan Windham-Bannister. Photo by Kimberly Moa.

The Massachusetts Life Sciences Center cuts a high profile these days. Created by the state Legislature in June 2006 to foster research and economic development in the Commonwealth’s substantial life science sector, the center has money to burn, thanks to the Life Sciences Act the Bay State passed last year.

Led Susan Windham-Bannister, a former healthcare policy wonk turned business strategy consultant turned state life sciences czar, the quasi-public agency is charged with dispensing a mix of public and private funding to cultivate the state’s medical device, biotech and pharmaceutical sectors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA Database Search


FDAzilla

Search the FDA's 510(k) and PMA database instantly.

Features

J. Raymond Elliott left an indelible mark on med-tech goliath Boston Scientific during two years in the corner office. As he passes the torch to interim CEO Hank Kucheman, MassDevice looks back on one of the most boisterous CEOs in the device space.

AccuVein CEO Ron Goldman tells MassDevice about his firm's hand-held vascular imaging technology.

Stu Randle, CEO of GI Dynamics, discusses the company's recent Australian IPO in an interview with MassDevice.

Mela Sciences CEO Joseph Gulfo tells MassDevice about the path from nearly assured clearance in June 2009 to the brink of clearance more than two years later.

Former Medtronic CEO Bill Hawkins, in an exclusive interview with MassDevice.com, tells us about the one that got away: Guidant Corp.'s stent-making operation.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp